Take­da flash­es red light on 'break­through' nar­colep­sy drug af­ter PhII tri­als turned up mys­te­ri­ous safe­ty sig­nal

Take­da is bring­ing two Phase II nar­colep­sy tri­als to a pre­ma­ture end in the af­ter­math of a “safe­ty sig­nal.”

The tri­als test­ed TAK-994 as a treat­ment for both type 1 and type 2 nar­colep­sy. It’s one of mul­ti­ple oral orex­in ag­o­nists that the phar­ma gi­ant has been de­vel­op­ing to tar­get the chron­ic sleep-wake dis­or­der.

In­ves­ti­ga­tors have stopped dos­ing pa­tients as a pre­cau­tion­ary mea­sure, the com­pa­ny said, with­out dis­clos­ing what ex­act­ly went wrong. The cur­rent pri­or­i­ty is on “time­ly in­ter­pre­ta­tion of the ben­e­fit/risk pro­file of TAK-994 and to de­ter­mine next steps for the pro­gram.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.